Compare DuPont de Nemours Inc (DD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Revvity Inc — how do they compare? DuPont de Nemours Inc trades at $131.75 (market cap $17.70B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: DuPont de Nemours Inc and Revvity Inc are close in size by market cap, and DuPont de Nemours Inc pays the higher dividend (1.83%). Which is the better fit depends on your goals — on Pluang, investors hold DuPont de Nemours Inc for 89 Days and Revvity Inc for 12 Days on average.
| DD | RVTY | |
|---|---|---|
Market Cap | $17.70B | $17.14B |
Volume | 638,303 | 2,226,396 |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $157.36 |
52-Week Low | $92.49 | $82.26 |
Typical Hold Time | 89 Days | 12 Days |
Enterprise Value | $19.09B | $19.46B |
Dividend Yield | 1.83% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $131.08, down 1.65% on the day, with neutral technical signals from moving averages and oscillators. The company shows mixed fundamentals with recent earnings beats but declining revenue from $12.4B in 2024 to $6.85B in 2025, resulting in a net loss of $779M. Analyst sentiment remains positive with 58.5% buy ratings, though the consensus price target of $95 suggests caution. Recent developments include new product launches in sugar separation technology and Tyvek innovations, alongside ongoing PFAS litigation settlements.
The outlook for DD hinges on margin recovery and growth in key sectors like healthcare and water technologies, but investors face risks from legal liabilities, volatile cash flows, and high P/E valuation. Institutional activity shows mixed signals with both position reductions and significant increases, reflecting uncertainty about near-term performance amid structural growth opportunities.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
